Topic: oral drug delivery platform
Attend this complimentary webinar on patient-centric drug development and advanced ODT technologies in Japan and the US.
Rani completed the first human safety study of its oral capsule designed to deliver injectable biologic therapies from within the digestive tract.
MIT and Novo Nordisk scientists have come up with an oral insulin delivery system that shows promise in lowering glucose levels in animal studies.
The agreement sees Amgen pay a “modest” upfront fee to access Entera’s technology and commit to up to $270 million in milestones.
The pact gives Roche access to PureTech’s milk-derived exosome technology in return for up to $36 million in near-term payments.
If successful in further trials, OPRX-106 could mount a challenge in the market for injectable and infused TNF drugs.
The investment equips Rani to step up manufacturing of its robotic, oral biologic delivery pill in anticipation of moving the devices into the clinic.
The project is built upon a device Rani designed to enable the oral delivery of proteins and other molecules that are currently injected.
Johnson & Johnson has landed rights to Protagonist Therapeutics’ preclinical Crohn’s disease asset PTG-200.
KeyBioscience has turned to Enteris BioPharma for help creating oral formulations of a metabolic peptide.